Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Beate Niemeier"'
Autor:
Christian Geßner, Thomas Fietz, Christoph Losem, Andreas Lück, Holger Schulz, Beate Niemeier, Matthias Groschek, Henning Eschenburg, Rudolf Weide, Albrecht Kretzschmar, Nikolaj Frost, Joachim Hipp, Johanna Harde, Christiane D. Matillon, Sina Grebhardt, Karin Potthoff
Publikováno v:
Current Medical Research and Opinion. 38:2191-2199
Real-world evidence on the application of the granulocyte colony-stimulating factor lipegfilgrastim for the reduction of chemotherapy-induced neutropenia and febrile neutropenia (FN) is limited. The NADIR study aimed to evaluate effectiveness and saf
Autor:
Beate Niemeier, Michael Neise, Christoph Losem, Johanna Harde, Ali Aldaoud, Johann Mittermueller, Wolfgang Knauf, Karin Potthoff, Tanja Trarbach
Publikováno v:
Leukemia Research. 68:90-97
Lenalidomide (LEN) is an immunomodulatory drug with significant clinical activity against relapsed and refractory multiple myeloma (r/r MM). Based on the pivotal phase 3 trials MM-009 and MM-010, LEN in combination with dexamethasone (DEX) is approve
Autor:
Jürgen Wehmeyer, Beate Niemeier, Matthias Zaiss, Hanns-Detlev Harich, Christoph Losem, Johanna Harde, Karin Potthoff, Judith Müller, Hans Werner Tessen, Carla Hannig, Stephan Schmitz, Martine Klausmann
Publikováno v:
European journal of haematology. 101(6)
Objective Azacitidine (Vidaza® ) is the standard treatment for patients with higher-risk myelodysplastic syndromes (MDS) not eligible for allogeneic stem cell transplantation. In the noninterventional study PIAZA, we evaluated the effectiveness and